118,802 Bristol Myers Squibb Company $BMY Shares Purchased by TD Waterhouse Canada Inc.

Key Points

• TD Waterhouse Canada increased its Bristol Myers Squibb stake by 145.7% in the third quarter, purchasing 118,802 shares and bringing its holdings to 200,328 shares valued at approximately $12.5 million. Institutional investors collectively own 76.41% of BMY.
• Bristol Myers Squibb reported stronger-than-expected quarterly results, with $2.04 earnings per share and $12.97 billion in revenue, while positive Phase 3 data for RYZ101 and iberdomide support efforts to replace aging-drug revenue.
• The company maintains a $0.63 quarterly dividend, equivalent to a 4.2% yield, but investors remain cautious because of its roughly $43 billion debt load and looming patent expirations. Analysts’ average rating is “Moderate Buy,” with a consensus price target of $64.88.

TD Waterhouse Canada Inc. boosted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 145.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 200,328 shares of the biopharmaceutical company's stock after buying an additional 118,802 shares during the period. TD Waterhouse Canada Inc.'s holdings in Bristol Myers Squibb were worth $12,500,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of BMY. Eagle Bay Advisors LLC raised its holdings in shares of Bristol Myers Squibb by 2.6% in the third quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company's stock valued at $408,000 after buying an additional 168 shares during the last quarter. Boltwood Capital Management grew its holdings in Bristol Myers Squibb by 2.5% during the 3rd quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company's stock worth $443,000 after acquiring an additional 170 shares during the last quarter. Sandy Cove Advisors LLC grew its holdings in Bristol Myers Squibb by 4.7% during the 2nd quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company's stock worth $227,000 after acquiring an additional 176 shares during the last quarter. Key Financial Inc grew its holdings in Bristol Myers Squibb by 2.4% during the 1st quarter. Key Financial Inc now owns 7,939 shares of the biopharmaceutical company's stock worth $482,000 after acquiring an additional 183 shares during the last quarter. Finally, Cornerstone Planning Group LLC increased its position in Bristol Myers Squibb by 29.8% in the 1st quarter. Cornerstone Planning Group LLC now owns 801 shares of the biopharmaceutical company's stock valued at $46,000 after acquiring an additional 184 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Recent late-stage data support the company’s effort to replace revenue from aging medicines. Bristol Myers Squibb reported positive Phase 3 topline results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The breadth of the pipeline could strengthen long-term growth if the programs successfully reach the market. How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
• Positive Sentiment: Admilparant remains potentially viable as a pulmonary-fibrosis treatment despite mixed Phase 3 results, with UBS reportedly maintaining a constructive view. The lower dose met the primary endpoint, preserving some commercial potential. Bristol-Myers Squibb's Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Neutral Sentiment: BMY’s roughly 40% one-year rally has been supported by new medicines, revenue growth and higher earnings guidance. However, its low valuation—about 9.36 times forward earnings—suggests investors remain cautious about whether the new portfolio can justify additional upside. Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
• Negative Sentiment: The company’s approximately $43 billion debt load and looming patent cliff create concerns about future cash flow and dividend growth. Bristol Myers Squibb’s 4.2% yield and 17-year record of dividend increases may be attractive, but investors are questioning whether upcoming launches can offset declining legacy-drug revenue. Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $59.69 on Monday. The firm has a fifty day moving average of $63.55 and a two-hundred day moving average of $60.30. The stock has a market capitalization of $121.94 billion, a price-to-earnings ratio of 13.15, a PEG ratio of 0.30 and a beta of 0.19. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the business posted $1.46 EPS. The firm's quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities research analysts predict that Bristol Myers Squibb Company will post 6.56 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb's dividend payout ratio is presently 55.51%.

Analyst Ratings Changes

A number of equities analysts have weighed in on BMY shares. The Goldman Sachs Group raised shares of Bristol Myers Squibb from a "hold" rating to a "strong-buy" rating in a research note on Friday. TD Cowen started coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "buy" rating on the stock. Cantor Fitzgerald decreased their price target on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a "neutral" rating on the stock in a research note on Thursday, October 8th. HSBC reissued a "hold" rating and issued a $65.00 price target (up from $60.00) on shares of Bristol Myers Squibb in a report on Thursday, September 10th. Finally, Wall Street Zen upgraded shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Moderate Buy" and a consensus price target of $64.88.

Insiders Place Their Bets

In other news, SVP Phil M. Holzer sold 500 shares of the business's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.05% of the company's stock.

Bristol Myers Squibb Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.